Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Klaus Brischwein"'
Autor:
Eva Krinner, Patrick Hoffmann, Peter Kufer, Bernd Schlereth, Patrick A. Baeuerle, Klaus Brischwein, Cornelia Haas, Ralf Lutterbüse
Publikováno v:
Immunobiology. 214:441-453
MT110 is an EpCAM/CD3-bispecific antibody construct in clinical development for the treatment of patients with adenocarcinoma expressing EpCAM (CD326). Like other members of this antibody class, MT110 can engage resting, polyclonal CD8(+) and CD4(+)
Autor:
Bernd Schlereth, Hauke Winter, Barbara Mayer, Juliane Witthauer, Klaus Brischwein, Karl-Walter Jauch, Patrick A. Baeuerle, Ilona Funke
Publikováno v:
Breast Cancer Research and Treatment. 117:471-481
In the present study, the efficacy of a new drug, i.e. the bispecific single-chain antibody MT110 targeting the epithelial antigen EpCAM and the T-cell antigen CD3 was tested ex vivo in malignant pleural effusions (MPEs). EpCAM+ epithelial cells were
Autor:
Eva Vieser, Bernd Schlereth, Roman Kischel, Matthias G. Friedrich, Klaus Brischwein, Patrick A. Baeuerle, Maria Amann, Petra Lutterbuese, Peter Kufer, Grit Lorenczewski, Laetitia Petersen
Publikováno v:
Cancer Immunology, Immunotherapy. 58:95-109
MuS110 is a BiTE antibody bispecific for murine EpCAM (CD326) and murine CD3. A recent study has shown that microS110 has significant anti tumor activity at well-tolerated doses as low as 5 microg/kg in orthotopic breast and lung cancer models (Amann
Autor:
Sandrine Crommer, Patrick Hoffmann, Patrick A. Baeuerle, Peter Kufer, Michael Molhoj, Klaus Brischwein, Mirnaalini Sriskandarajah, Doris Rau, Robert Hofmeister
Publikováno v:
Molecular Immunology. 44:1935-1943
Many kinds of bispecific antibodies recruiting T cells for cancer therapy have been developed. Side-by-side comparison has shown that CD19-/CD3-bispecific antibodies of the diabody, tandem diabody (Tandab) and quadroma format had similar cytotoxic ac
Autor:
Robert Hofmeister, Nadja Prang, Sandrine d’Argouges, Klaus Brischwein, JoAnn Suzich, Christian Brandl, Cornelia Haas, Peter Kufer, Tanja Fisch, Ralf C. Bargou, Patrick A. Baeuerle
Publikováno v:
Cancer Immunology, Immunotherapy. 56:1551-1563
BiTE molecules comprise a new class of bispecific single-chain antibodies redirecting previously unstimulated CD8+ and CD4+ T cells for the elimination of target cells. One example is MT103 (MEDI-538; bscCD19xCD3), a CD19-specific BiTE that can induc
Autor:
Bernd Schlereth, Sandrine Crommer, Antonio J. da Silva, Robert Hofmeister, Grit Lorenczewski, Mathias Locher, Laetitia Petersen, Klaus Brischwein, Patrick A. Baeuerle, Sandra Lippold, Petra Lutterbuese
Publikováno v:
Cancer Immunology, Immunotherapy. 56:459-468
An important mode of action shared by human IgG1 antibody therapies is antibody-dependent cellular cytotoxicity (ADCC). ADCC relies on the interaction of the antibody's Fc portion with Fc-gama receptors (FcgammaR) on immune effector cells. The anti-t
Autor:
Bernd Schlereth, Mathias Locher, Pauline Wimberger, Benjamin Guller, Thomas Urbig, Sonja Offner, Ralf Lutterbuese, Robert Hofmeister, Andreas Wolf, Iduna Fichtner, Antonio J. da Silva, Rainer Kimmig, Tobias Raum, Peter Kufer, Klaus Brischwein, Carola Steiger, Petra Kleindienst, Patrick A. Baeuerle
Publikováno v:
Molecular Immunology. 43:1129-1143
We have developed a novel single-chain Ep-CAM-/CD3-bispecific single-chain antibody construct designated MT110. MT110 redirected unstimulated human peripheral T cells to induce the specific lysis of every Ep-CAM-expressing tumor cell line tested. MT1
Autor:
Antonio J. da Silva, Petra Kleindienst, Roman Kischel, Sandra Lippold, Klaus Brischwein, Iduna Fichtner, Patrick A. Baeuerle, Bernd Schlereth, Mathias Locher, Ralf Lutterbüse, Grit Lorenczewski, Peter Kufer
Publikováno v:
Cancer Immunology, Immunotherapy. 55:785-796
Bispecific single-chain antibody constructs specific for human CD3 have been extensively studied for antitumor activity in human xenograft models using severe combined immunodeficient mice supplemented with human T cells. High efficacy at low effecto
Autor:
Klaus Brischwein, Bernd Schlereth, Rainer Kimmig, Grit Lorenczewski, Pauline Wimberger, Petra Kleindienst, Iduna Fichtner, Patrick A. Baeuerle, Ralf Lutterbuese, Ilse Junghahn, Peter Kufer, Antonio J. da Silva, Sabine Kasimir-Bauer
Publikováno v:
Cancer Research. 65:2882-2889
Bispecific T-cell engager (BiTE) are a class of bispecific single-chain antibodies that can very effectively redirect cytotoxic T cells for killing of tumor target cells. Here, we have assessed the in vivo efficacy of one representative, called bscEp
Autor:
Christian Brandl, Klaus Brischwein, Sandrine Crommer, Patrick Hoffmann, Robert Hofmeister, Nadja Prang, Patrick A. Baeuerle, Christian Itin, Ralf C. Bargou
Publikováno v:
International Journal of Cancer. 115:98-104
Certain bispecific antibodies exhibit an extraordinary potency and efficacy for target cell lysis by eliciting a polyclonal T-cell response. One example is a CD19-/CD3-bispecific single-chain antibody construct (bscCD19xCD3), which at femtomolar conc